A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD
Public ClinicalTrials.gov record NCT03508700. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 40-week Open-Label Extension Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD
Study identification
- NCT ID
- NCT03508700
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Tonix Pharmaceuticals, Inc.
- Industry
- Enrollment
- 93 participants
Conditions and interventions
Conditions
Interventions
- TNX-102 SL 5.6 mg Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 18, 2018
- Primary completion
- Sep 29, 2019
- Completion
- Sep 29, 2019
- Last update posted
- Feb 4, 2025
2018 – 2019
United States locations
- U.S. sites
- 16
- U.S. states
- 11
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Little Rock | Little Rock | Arkansas | 72211 | — |
| Beverly Hills | Beverly Hills | California | 90210 | — |
| Oceanside | Oceanside | California | 92056 | — |
| Orange | Orange | California | 92868 | — |
| Temecula | Temecula | California | 92591 | — |
| Colorado Springs | Colorado Springs | Colorado | 80910 | — |
| Norwich | Norwich | Connecticut | 06360 | — |
| Tampa | Tampa | Florida | 33609 | — |
| Atlanta | Atlanta | Georgia | 30341 | — |
| New Bedford | New Bedford | Massachusetts | 02740 | — |
| Las Vegas | Las Vegas | Nevada | 89102 | — |
| Cedarhurst | Cedarhurst | New York | 11516 | — |
| New York | New York | New York | 10128 | — |
| Canton | Canton | Ohio | 44718 | — |
| Cincinnati | Cincinnati | Ohio | 45219 | — |
| Oklahoma City | Oklahoma City | Oklahoma | 73103 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03508700, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 4, 2025 · Synced Apr 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03508700 live on ClinicalTrials.gov.